Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke
Phase of Trial: Phase II/III
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Allogeneic stem cell therapy Athersys (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms TREASURE
- Sponsors Healios
- 11 Oct 2017 Status changed from not yet recruiting to recruiting, according to an Athersys media release.
- 20 Mar 2017 According to an Athersys media release, this trial has received a priority review designation, enabling acceleration of the potential assessment time to six months for Japans Pharmaceutical and Medical Devices Agency review
- 23 Feb 2017 According to an Athersys media release, trial overview will be presented at the International Stroke Conference 2017.